SEC Company Response from NANOVIRICIDES, INC. (NNVC) (CIK 0001379006) (NNVC) — Apr 20, 2017
NANOVIRICIDES, INC. (NNVC) (CIK 0001379006)
Date: April 20, 2017 · CIK: 0001379006 · Accession: 0001144204-17-021300
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-216345
Letter
Nanotechnology-Enabled Targeted Viricides
Publicly Traded Company, “NNVC”
www.nanoviricides.com
April 20,
Via Edgar Only
United States Securities and Exchange Commission
Mail Stop 6010
Washington, D.C. 20549
Re: NanoViricides, Inc.
Registration Statement on Form S-3
Filed on March 1, 2017
File No. 333-216345
To Whom It May Concern:
Please be advised that the undersigned is the duly elected Chief Executive Officer of NanoViricides, Inc. (the "Registrant").
Having been advised that the Commission has no comments to the Registrant's Registration Statement on Form S-3 (File No. 333-216345) filed on March 1, 2017, and subsequently amended, the Registrant hereby requests acceleration of the effective date of the Registration Statement to Tuesday, April 25, 2017 at 10:00 a.m., or as soon thereafter as practicable.
The Registrant hereby acknowledges that:
· should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Should you have any questions in regard to this correspondence or any other matter relating to this Registrant’s filing, please do not hesitate to contact me.
Very truly yours,
/s/ Eugene Seymour, MD, MPH
Show Raw Text
CORRESP
1
filename1.htm
Nanotechnology-Enabled
Targeted Viricides
Publicly
Traded Company, “NNVC”
www.nanoviricides.com
April 20,
2017
Via Edgar Only
United States Securities and Exchange Commission
Mail Stop 6010
Washington, D.C. 20549
Re:
NanoViricides, Inc.
Registration Statement on Form S-3
Filed on March 1, 2017
File No. 333-216345
To Whom It May Concern:
Please be advised that
the undersigned is the duly elected Chief Executive Officer of NanoViricides, Inc. (the "Registrant").
Having been
advised that the Commission has no comments to the Registrant's Registration Statement on Form S-3 (File No. 333-216345)
filed on March 1, 2017, and subsequently amended, the Registrant hereby requests acceleration of the effective date of the
Registration Statement to Tuesday, April 25, 2017 at 10:00 a.m., or as soon thereafter as practicable.
The Registrant hereby acknowledges that:
· should
the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission
from taking any action with respect to the filing;
· the
action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve
the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the
Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission
or any person under the federal securities laws of the United States.
Should you have any
questions in regard to this correspondence or any other matter relating to this Registrant’s filing, please do not hesitate
to contact me.
Very truly yours,
/s/ Eugene Seymour, MD, MPH
Eugene Seymour, MD, MPH
1 Controls Drive, Shelton,
CT 06484. Tel./Fax: 203-937-6137.